LEO Pharma Archives -

Leo puts target on Dupixent in US as FDA clears tralokinumab

Phil Taylor AbbVie, atopic dermatitis, Cibinqo, dermatology, Eli Lilly, lebrikizumab, LEO Pharma, Olumiant, Pfizer, Regeneron, regulatory approval, Rinvoq, Sanofi, tralokinumab 0 Comment

Sanofi and Regeneron have another challenger to their big-selling drug Dupixent for atopic dermatitis, now that the FDA

Leo puts target on Dupixent in US as FDA clears tralokinumab

https://pharmaphorum.com/news/leo-puts-target-on-dupixent-in-us-as-fda-clears-tralokinumab/

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

LEO Pharma’s new R&D lead on driving agility in drug development

mike.hammerton@pharmaphorum.com Deep Dive, Jörg Möller, LEO Pharma, patient-centric, R&D, Research and Development 2021 0 Comment

After 27 years at Bayer, Jörg Möller has moved to LEO Pharma as the company’s EVP, global research

LEO Pharma’s new R&D lead on driving agility in drug development

https://pharmaphorum.com/r-d/views-analysis-r-d/leo-pharma-rd-lead-agility-drug-development/

Deep Dive/ R&D/ Views & Analysis/ Views and analysis

Deep Dive: Research and Development

mike.hammerton@pharmaphorum.com AI, clinical trials, digital health, LEO Pharma, NIHR, rare disease 0 Comment

Pharma’s historic R&D efforts have given us some light at the end of the COVID tunnel. Now it’s

Deep Dive: Research and Development

https://pharmaphorum.com/r-d/views-analysis-r-d/deep-dive-research-and-development/

Podcast/ Sales and Marketing/ Video/ Views & Analysis/ Views and analysis

Gitte Aabo on telemedicine and GN Hearing: the pharmaphorum podcast

Dominic Tyer COVID-19, Gitte Aabo, GN Hearing, LEO Pharma, podcast, telemedicine 0 Comment

Joining the pharmaphorum podcast for episode 24 is Gitte Aabo, who last year moved to hearing aid technology

Gitte Aabo on telemedicine and GN Hearing: the pharmaphorum podcast

https://pharmaphorum.com/sales-marketing/gitte-aabo-telemedicine-podcast/

News/ News/ Sales and Marketing

LEO eyeing 2021 US launch for eczema drug tralokinumab

Richard Staines atopic dermatitis, dermatology, Dupixent, LEO Pharma, Sanofi, tralokinumab 0 Comment

LEO Pharma is gearing up to launch its eczema drug tralokinumab next year after submitting a filing to the

LEO eyeing 2021 US launch for eczema drug tralokinumab

https://pharmaphorum.com/news/leo-eyeing-2021-us-launch-for-eczema-drug-tralokinumab/

Market Access/ News/ News

Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EU

Phil Taylor atopic dermatitis, dermatology, Dermira, Dupixent, Eli Lilly, LEO Pharma, Pfizer, Sanofi, tralokinumab 0 Comment

The EMA has started a review of Leo Pharma’s interleukin-13 inhibitor tralokinumab as an antibody therapy for atopic

Eyeing Dupixent’s territory, Leo Pharma files tralokinumab in EU

https://pharmaphorum.com/news/eyeing-dupixents-territory-leo-pharma-files-tralokinumab-in-eu/

Patients/ Views & Analysis/ Views and analysis

Towards Patient Centricity: LEO Pharma

Amanda Barrell LEO Pharma, patient centricity, psoriasis, Towards Patient Centricity 0 Comment

Industry plays a pivotal role in making sure patient needs are not overlooked by the wider healthcare community.

Towards Patient Centricity: LEO Pharma

https://pharmaphorum.com/views-analysis-patients/towards-patient-centricity-leo-pharma/

Digital/ News/ News/ News/ Oncology

Smartphone app provides skin cancer early warning service

Richard Staines digital health, LEO Pharma, skin cancer, SkinVision 0 Comment

The makers of a smartphone app are hoping that it could be used to play a crucial role

Smartphone app provides skin cancer early warning service

https://pharmaphorum.com/news/smartphone-app-provides-skin-cancer-early-warning-service/

Market Access/ R&D/ Views & Analysis/ Views & Analysis/ Views and analysis

Almirall gets in on the eczema action

Richard Staines Almirall, atomic dermatitis, Dupixent, eczema, LEO Pharma, Sanofi 0 Comment

Sanofi’s Dupixent has shown there is a market for biologic drugs to treat eczema, and now Spain’s Almirall

Almirall gets in on the eczema action

https://pharmaphorum.com/views-analysis-market-access/almirall-gets-in-on-the-eczema-action/

Trending

LEO Pharma

Login